Results 21 to 30 of about 231,349 (305)

Immune checkpoint inhibitors [PDF]

Journal of Experimental Medicine, 2021
Three papers by James Allison and Tasuku Honjo published in JEM between 1995 and 2000 crystallized seminal insights into the role of CTLA-4 and PD-1 in immunosuppression (Krummel and Allison. 1995. J. Exp. Med.https://doi.org/10.1084/jem.182.2.459; van Elsas et al. 1999. J. Exp. Med.https://doi.org/10.1084/jem.190.3.355; Freeman et al. 2000. J.
Kroemer, Guido, Zitvogel, Laurence
openaire   +3 more sources

Immune Checkpoint Inhibitors and the Heart [PDF]

Frontiers in Cardiovascular Medicine, 2021
Immune checkpoint inhibitors (ICIs) represent a break-through treatment for a large number of cancer types. This treatment is increasingly being recommended. ICIs are prescribed for primary tumours and for metastases, adjuvant/neo-adjuvant therapy.
Diana Larisa Mocan-Hognogi, Diana Larisa Mocan-Hognogi, Sebastian Trancǎ, Sebastian Trancǎ, Anca Daniela Farcaş, Anca Daniela Farcaş, Radu Florin Mocan-Hognogi, Radu Florin Mocan-Hognogi, Andrada Viorica Pârvu, Andrada Viorica Pârvu, Anca Simona Bojan, Anca Simona Bojan   +11 more
openaire   +3 more sources

Checkpoint Inhibitors [PDF]

Deutsches Ärzteblatt international, 2019
Treatment with checkpoint inhibitors such as anti-programmed death-1 (anti-PD-1), anti-PD-ligand 1 (anti-PD-L1), and anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) antibodies can prolong the survival of cancer patients, but it also induces autoimmune side effects in 86-96% of patients by activating the immune system.
Lucie, Heinzerling, Enrico N, de Toni, Georg, Schett, Gheorghe, Hundorfean, Lisa, Zimmer   +4 more
openaire   +2 more sources

Checkpoint inhibitors and arthritis [PDF]

Annals of the Rheumatic Diseases, 2019
It was with interest that we read the article by Belkhir et al 1 in the recent Annals of Rheumatic Disease . The article described the first report of rheumatoid arthritis (RA) and polymyalgia rheumatica developing after the use of immune checkpoint inhibitors to treat a variety of cancers.
Nicholas, Manolios, Leslie, Schrieber
openaire   +2 more sources

Structure and Optimization of Checkpoint Inhibitors [PDF]

Cancers, 2019
With the advent of checkpoint inhibitor treatment for various cancer types, the optimization of drug selection, pharmacokinetics and biomarker assays is an urgent and as yet unresolved dilemma for clinicians, pharmaceutical companies and researchers.
Picardo, Sarah L., Doi, Jeffrey, Hansen, Aaron R.   +2 more
openaire   +4 more sources

Immune checkpoint inhibitors in malignancy [PDF]

Australian Prescriber, 2019
Immune checkpoints normally stop the body from mounting an immune response against healthy cells. Some cancers can acquire these checkpoints so that the tumour cells are not recognised by the immune systemInhibiting the checkpoints therefore enables the tumour cells to be recognised and allows an immune response to be activated against themImmune ...
Luke, Ardolino, Anthony, Joshua
openaire   +2 more sources

Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population‐based cohort study [PDF]

, 2023
Background Immune checkpoint inhibitors (ICIs) are increasingly established cancer therapeutics, but they are associated with new-onset diabetes mellitus (DM).
Kong, Dicken, Tse, Gary, Lee, Y., Wong, Wing Tak, Chan, J., Ng, Kenrick, Dee, E., Lakhani, I., Lee, Sharen, Tang, Pias, Liu, T., Satti, Danish Iltaf   +11 more
core   +1 more source

Novel Delivery Systems for Checkpoint Inhibitors

Medicines, 2019
Checkpoint inhibition (CPI) therapies have been proven to be powerful clinical tools in treating cancers. FDA approvals and ongoing clinical development of checkpoint inhibitors for treatment of various cancers highlight the immense potential of ...
Purushottam Lamichhane, Rahul Deshmukh, Julie A. Brown, Silvia Jakubski, Priyanka Parajuli, Todd Nolan, Dewan Raja, Mary Badawy, Thomas Yoon, Mark Zmiyiwsky, Narottam Lamichhane   +10 more
doaj   +1 more source

A Role of Therapy that Targets Immune Checkpoint Proteins for the Treatment of Melanoma Brain Metastasis, Liver, Breast, Pancreatic Cancer and Pancreatic Adenocarcinoma

مجله كليه طب الكندي, 2022
Checkpoint inhibitors are a type of immune therapy used to treat different types of cancers. These drugs block different checkpoint proteins, for example, CTLA-4, PD-1, and PD-L1 inhibitors.
Smaa Elsayed Mohammed, Basma Aml Youssef, Doaa Alaa Ghonai, Eman Fares Ahmed, Esraa Gharieb Mohammed, Mai Ashraf Abdo, Mai Essam Mohammed, Rana Gharieb Hassan, Reem Mohammed Mohammed, Rofida Ahmed Abd Al-Azeem, Sarah Adel Swelem, Sarah Ouda Salman, Sarah Mohammed Al-aiyq, Toka Taha Taha, Zainab Khalid Moawad   +14 more
doaj   +1 more source

Bub1 is a fission yeast kinetochore scaffold protein, and is sufficient to recruit other spindle checkpoint proteins to ectopic sites on chromosomes [PDF]

, 2007
The spindle checkpoint delays anaphase onset until all chromosomes have attached in a bi-polar manner to the mitotic spindle. Mad and Bub proteins are recruited to unattached kinetochores, and generate diffusible anaphase inhibitors.
Rischitor, Patricia E, Kevin G Hardwick, Rischitor Patricia E., Patricia E Rischitor, May, Karen M, Hardwick Kevin G., Hardwick, Kevin G, Karen M May, May Karen M.   +8 more
core   +1 more source